Press Releases Choose Year All Items 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Search Press Releases Found 265 Results May 12, 2015 Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering SECUREL(TM), its Abuse-Deterrent, Extended-Release, Technology Platform for Opioids April 21, 2015 Relmada Therapeutics Commences Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine April 16, 2015 Relmada Therapeutics Receives Health Canada Clearance to Further Explore Promising NMDA Receptor Antagonist d-Methadone (REL-1017) April 8, 2015 Relmada Therapeutics Appoints Lisa Nolan, Ph.D. as Senior Vice President of Business Development April 2, 2015 Relmada Therapeutics Set for Busy 2015 in Clinical Trials Developing Drugs for the Lucrative Pain Market March 24, 2015 Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine March 17, 2015 Relmada Therapeutics Reports Positive Phase 1 Results for NMDA Receptor Antagonist d-Methadone March 12, 2015 Relmada Therapeutics to Present at Future Leaders in the Biotech Industry Conference March 12, 2015 /C O R R E C T I O N — Relmada Therapeutics, Inc./ March 5, 2015 Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles «...222324252627
